Your weekly snapshot of clinically actionable genes from the ACMG Secondary Findings List
| Gene | Associated Condition | Gene-Disease Validity Classification (Interested in learning more? Click here!) |
|---|---|---|
| CACNA1S | CACNA1S-related malignant hyperthermia susceptibility | Moderate |
| CACNA1S-related hypokalemic periodic paralysis | Strong | |
| CACNA1S-related myopathy | Moderate |
Clinical Phenotype Summary:
The CACNA1S gene is located on chromosome 1 and encodes the voltage-dependent L-type calcium channel subunit alpha-1S. Pathogenic variants in this gene have been associated with CACNA1S-related malignant hyperthermia susceptibility (MHS) and CACNA1S-related hypokalemic periodic paralysis (hypoPP), which are both inherited in an autosomal dominant fashion, and CACNA1S-related myopathy, which can be inherited in an autosomal dominant or autosomal recessive fashion.
CACNA1S-related malignant hyperthermia susceptibility (MHS) is a highly variable condition and is characterized by:
- an increased risk of hypermetabolic reactions triggered by exposure to volatile anesthetics and/or depolarizing skeletal muscle relaxants
Diagnostic criteria for MHS include:
- respiratory and metabolic acidosis
- unexplained sinus or ventricular tachycardia
- ventricular fibrillation
- muscle rigidity and breakdown
- temperature increase with symptom onset occurring during or shortly after general anesthesia
CACNA1S-related hypokalemic periodic paralysis (hypoPP) is characterized by:
- episodic attacks of generalized weakness of the limbs with concomitant hypokalemia (serum potassium <3.5mEq/L)
Diagnostic criteria for hypoPP include a pathogenic alteration in a hypoPP-associated gene, exclusion of other causes of hypokalemia, and one of the following:
- ≥2 attacks of muscle weakness with documented hypokalemia OR
- one attack of muscle weakness in the proband and one attack of weakness in a relative with documented hypokalemia
Additional criteria include a pathogenic alteration in a hypoPP-associated gene and at least three of the following features:
- onset in the first or second decade of life
- duration of attack >2 hours
- improvement in symptoms with potassium intake
- family history of disease
- positive long exercise test
- the presence of triggers
Known triggers of attacks include carbohydrate-rich foods, alcohol, stress, fever, and rest after exercise. Slowly progressive myopathy independent of paralysis has been seen in a minority of patients.
CACNA1S-related myopathy is characterized by:
- severe weakness
- perinatal hypotonia
- motor delay
Other features seen in a minority of patients include:
- decreased fetal movements
- muscle atrophy
- ophthalmoplegia
- respiratory issues
- scoliosis
- pes equinus
- swallowing difficulties
Unique Considerations:
- Preoperative diagnosis of MH susceptibility is important for the safety of individuals with anticipated exposure to triggering agents.
- Diagnosis of MH susceptibility is established by in vitro contracture testing (IVCT) to assess the sensitivity of skeletal muscle to halothane and caffeine.
- Variable expressivity and reduced penetrance have been reported for MHS.
- The age of onset is typically between ages two and thirty for hypoPP.
- Penetrance has been reported to be approximately 90% in males and lower in females.
- In CACNA1S-related myopathy, the age of onset is typically in the neonatal period, but prenatal and infantile-onset of disease have been reported.
Clinical Resources:
Understanding your Secondary Findings Result
Ambry Genetics Gene-Disease Validity Scheme
Citations:
- Levano, 2017. PMID: 28259615
- Rosenberg, 2020. PMID: 32675688
- Sangkuhl, 2020. PMID: 31851124
- Statland, 2013. PMID: 24195946
- Weber, 2018. PMID: 20301512
- Hunter, 2015. PMID: 25983750
- Schartner, 2017. PMID: 28012042
- Yiş, 2019. PMID: 31215160
Upcoming Events:
- EducateNext: Thursday, November 12th, 2026, at 11:00 am PDT: “Beyond the Blind Spots: Solving the Unsolvable with UCI PMGRC & the GREGoR Consortium” with Seth Berger and Susan Toomey. Register here
- Webinar: Wednesday, November 18th, 2026, at 10:00 am PDT: “Uncovering the Complete Picture: Transforming Rare Disease Care for Every Patient” with TJ Slavin, MD. Register here
- EducateNext: Thursday, November 19th, 2026, at 11:00 am PDT: “Constitutional epimutations and their inheritance patterns” with Megan Hitchins. Register here
- EducateNext: Wednesday, December 2nd, 2026, at 10:00 am PDT: “Small Nuclear RNAs in Rare Disorders” with Nicky Whiffin. Register here
Each week, we explore a gene from the ACMG Secondary Findings list—genes identified by the American College of Medical Genetics and Genomics as having clear, actionable health implications. These genes are included because they’re linked to serious but preventable or manageable conditions when identified early.
To learn more about the ACMG Secondary Findings list, click here.
To read all previous Gene Scene emails, click here.